Table 1.
OATP1B1 Phenotype Information Included as Systems Parameters in the Updated Full PBPK Rosuvastatin Model*
| Phenotype | Diplotype | Polymorphisms Involved | Relative Abundance | CV (%) |
|---|---|---|---|---|
| Extensive transporter (ET) | *1a/*1a | c.521T>C, c.388A>G | 1 | 74 |
| *1a/*1b | c.521T>C, c.388A>G | |||
| *1a/*14 | c.521T>C, c.388A>G, c.463C>A | |||
| *1a/*35 | c.521T>C, c.388A>G, c.1929A>C | |||
| Intermediate transporter (IT) | *1a/*5 | c.521T>C, c.388A>G | 0.68 | 54 |
| *1a/*15 | c.521T>C, c.388A>G | |||
| *1b/*15 | c.521T>C, c.388A>G | |||
| *5/*14 | c.521T>C, c.388A>G, c.463C>A | |||
| *14/*15 | c.521T>C, c.388A>G, c.463C>A | |||
| Poor transporter (PT) | *5/*5 | c.521T>C, c.388A>G | 0.37 | 35 |
| *15*15 | c.521T>C, c.388A>G | |||
| *5/*15 | c.521T>C, c.388A>G |
*Frequency, relative abundance, and the related population variability of each phenotype were obtained from in‐house meta‐analysis of published studies.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 Diplotypes associated with each phenotype definition are also summarized. Note: all combinations of a given diplotype have been included in the model (eg, *1a/*1b and *1b/*1a) but for simplicity not included in this table.